navigation navigation
navigation

News

23 Jun 2020

Trilantic Europe supports add-on acquisitions to bolster its healthcare portfolio in Italy and Germany

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

9 Apr 2020

Trilantic Europe portfolio companies are actively providing resources and know-how as well as making in-kind philanthropic contributions to support health authorities in their fight against COVID-19

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

23 Oct 2019

Trilantic Europe fully exits its successful investment in Gamenet

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

4 Sep 2019

Trilantic Europe supports two bolt-on acquisitions for Oberberg

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

30 Jul 2019

Trilantic Europe partially monetises its investment in Gamenet

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

21 Nov 2018

Talgo awarded 2018 Internationalization Award

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

28 Sep 2018

YM&U joins forces with Trilantic Europe following rebrand

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

24 Jul 2018

Gamenet Group signed the agreement for the acquisition of 100% of GoldBet

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

15 Dec 2017

Trilantic Europe invests in the Oberberg Group

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

6 Dec 2017

Gamenet Group completed the listing on Borsa Italiana

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

4 Dec 2017

Elisabetta Franchi purchases 25% of Betty Blue S.p.A. from Trilantic Europe

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

2 Nov 2017

Talgo shortlisted for HS2 rolling stock procurement

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

1 Jun 2017

Trilantic Europe invests in leading bioethanol business in Spain and France

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

7 Apr 2017

Trilantic Europe becomes a shareholder in Pacha Group

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

28 Nov 2016

Talgo wins the most important high-speed tender in Europe with its new Avril, the most advanced high-speed train

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

24 Feb 2016

Trilantic Europe Invests In Maugeri, Leading Italian Non-Acute Private Hospital Operator

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

13 Oct 2015

Trilantic Europe completes acquisition of 90% stake in leading Italian pharmaceuticals producer Doppel Farmaceutici

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

1 Jul 2015

Trilantic Europe raises €900 million

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

1 Jul 2015

IPO of Trilantic Europe IV’s portfolio companies, Talgo and Euskaltel

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

26 Mar 2015

Prettl and Trilantic Europe announce a partnership agreement

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

14 Jan 2015

Trilantic Capital Partners has realised its investment in Clarion Events

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

17 Oct 2013

Trilantic acquires stake in Elisabetta Franchi

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

16 Sep 2013

Gamenet successfully issues €200mn in its debut bond offering

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

26 Jun 2013

Spain's Talgo Awarded €482 million Contract In Kazakhstan

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

20 Nov 2012

Trilantic Europe exits Istanbul Doors Group, owner of the leading restaurants in Istanbul and Tom Aiken’s restaurants in London

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

14 May 2012

Marex Spectron to acquire Schneider Trading Associates Pro-Trader Division

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

12 Dec 2011

Talgo manufacturing facility opens in Kazakhstan

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

26 Oct 2011

Talgo awarded the High-Speed Mecca-Medina mega-contract

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

12 Apr 2011

Michel Léonard joins Trilantic Capital Partners as operating partner

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

24 Mar 2011

The Istanbul Doors Restaurant Group Acquires the Restaurant Business of Michelin-Starred Chef Tom Aikens

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

22 Mar 2011

Marex Group Reaches Agreement to Acquire Spectron Group

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

14 Feb 2011

Appointment of John Danilovich to Trilantic European Advisory Council

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

17 Jan 2011

Refresco Group Announces its Intention to Acquire Spumador

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

14 Jan 2011

Trilantic Capital Partners commits up to €50 million in LeYa

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

7 Jan 2011

Trilantic Capital Partners to Invest €53 million in Gamenet

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

11 Nov 2010

Talgo is awarded the contract to renew and expand the intercity passenger train coaches of the national railway company of Kazakhstan

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

28 Jul 2010

Thai Union Frozen Products Board of Directors Approves Acquisition of MW Brands from Trilantic Capital Partners

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

10 Feb 2010

Trilantic Capital Partners has Successfully Realized its Ownership Stake in Industria de Turbo Propulsores S.A.

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

24 Sep 2009

Talgo: Spanish Minister of Transportation to Support Talgo in its Internationalization

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

17 Jul 2009

Talgo: Governor Doyle Announces Agreement with Talgo to Bring New Trains, Assembly and Maintenance Facilities to Wisconsin

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

9 Apr 2009

Istanbul Doors: Group Launches New Italian Restaurant Concepts

Trilantic Europe today announces that it has supported 7 add-on acquisitions across its portfolio companies since the start of 2020.

Trilantic Europe’s portfolio company, Doppel Farmaceutici, agreed on 21 May 2020 to acquire 90% of Dietopack, a leading Italian family-owned contract manufacturing organisation (“CDMO”) founded in 2000 and headquartered in Emilia Romagna.

With 60 employees, the company focuses on nutraceutical products (representing 80% of revenues) and pet nutritionals, producing probiotics, vitamins, minerals, nutritional supplements and high protein dietary supplements mainly distributed through pharmacies by its clients. Dietopack adopts a full-service approach and is engaged in all phases of the value chain including product development, regulatory, production, packaging and analysis.

This acquisition was preceded by a meticulous search by Doppel and the Trilantic Europe team for suitable add-on acquisitions with a focus on nutraceuticals, a high growth sector supported by increasing customer demand. The sector has been resilient to the Covid-19 outbreak as demand for nutritional supplements and vitamins that support immune systems has increased during this period.

Doppel also expects to generate significant synergies by introducing its multinational pharmaceutical clients to Dietopack and leveraging the R&D capabilities of Doppel’s newly launched early-stage lab.

Doppel’s acquisition of Dietopack creates a larger, more diversified and fully integrated CDMO operator offering pharmaceutical, nutraceutical and pet products to its client base, further consolidating the company’s market leading position as the second largest CDMO in Italy.

Dietopack represents the 7th add-on acquisition across Trilantic Europe’s healthcare portfolio over the past six months. In addition to Doppel, Trilantic Europe has three other healthcare investments, one in Italy and two in Germany, namely Maugeri, Oberberg and Care Home Group. Since early March 2020, management’s efforts across Trilantic Europe’s healthcare portfolio companies have been focused on tightly managing facilities to protect the health and safety of its residents and employees, while executing the planned buy-and-build strategies.

Vittorio Pignatti, Chairman of Trilantic Europe commented: “The recent add-on acquisitions executed by our healthcare portfolio companies show that our continued focus on growth through active buy-and-build strategies is working even in today’s  challenging environment. Our portfolio of investments, which has always been prudently levered, is in a robust financial position despite the Covid-19 pandemic and we have material dry powder and bandwidth to accelerate growth initiatives across our businesses. We expect to complete other attractive add-ons and, in our sectors of focus, new platform investments over the coming months”.

Enquiries

For further information, contact Trilantic Europe - investorrelations@trilanticeurope.com

About Trilantic Europe

Trilantic Europe is a leading private equity firm focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services.

Contact

Trilantic Europe

London

35 Portman Square
London, W1H 6LR
United Kingdom

Guernsey

Trafalgar Court
St Peter Port
Guernsey, GY1 4LY

Luxembourg

26 Bd Royal
L-2449 Luxembourg
Luxembourg